

BC

**VITRONECTIN RECEPTOR ANTAGONISTS****Publication number:** JP10504808T**Publication date:** 1998-05-12**Inventor:****Applicant:****Classification:****- International:**

A61K31/415; A61K31/4184; A61K31/44; A61K31/4427;  
A61K31/443; A61K31/445; A61K31/454; A61K31/47;  
A61K31/495; A61K31/496; A61K31/55; A61K31/551;  
A61P9/10; A61P19/10; A61P29/00; A61P35/00;  
A61P43/00; C07D223/16; C07D233/56; C07D233/64;  
C07D235/14; C07D235/20; C07D243/14; C07D401/06;  
C07D401/12; C07D401/14; C07D403/06; C07D403/12;  
C07D403/14; C07D405/12; C07D405/14; C07D413/12;  
C07D417/12; C07D471/04; C07D491/04; C07D491/056;  
A61K31/415; A61K31/4164; A61K31/44; A61K31/4427;  
A61K31/445; A61K31/4523; A61K31/47; A61K31/495;  
A61K31/496; A61K31/55; A61K31/551; A61P9/00;  
A61P19/00; A61P29/00; A61P35/00; A61P43/00;  
C07D223/00; C07D233/00; C07D235/00; C07D243/00;  
C07D401/00; C07D403/00; C07D405/00; C07D413/00;  
C07D417/00; C07D471/00; C07D491/00; (IPC1-7):  
C07D243/14; C07D235/14; A61K31/415; A61K31/44;  
A61K31/445; A61K31/47; A61K31/495; A61K31/55;  
C07D235/20; C07D401/12; C07D401/14; C07D403/06;  
C07D403/12; C07D403/14; C07D405/12; C07D405/14;  
C07D413/12; C07D417/12; C07D471/04

**- European:**

C07D223/16C; C07D235/14; C07D243/14; C07D401/06;  
C07D401/12; C07D401/14; C07D403/12; C07D403/14;  
C07D413/12; C07D417/12; C07D471/04; C07D491/04

**Application number:** JP19950503462T 19950629**Priority number(s):** WO1995US08306 19950629; US19940267695  
19940629; US19950428933 19950425**Also published as:**

WO9600730 (A1)  
EP0767792 (A1)  
EP0767792 (A0)  
CA2193966 (A1)  
BR9508178 (A)

more &gt;&gt;

**Report a data error here**

Abstract not available for JP10504808T

Abstract of corresponding document: **WO9600730**

Compounds are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. These compounds comprise a fibrinogen receptor antagonist template linked to a heterocyclic moiety.

Data supplied from the esp@cenet database - Worldwide